GlucoTrackGCTK
GCTK
About: GlucoTrack Inc is a medical device company. It is focused on defining novel approaches that make diabetes management more accurate and convenient for daily living. The company has developed the GlucoTrack model that measures real-time blood glucose levels. The Company is developing an long-term implantable continuous blood glucose monitoring (CBGM) system, built on proven healthcare technologies. It is designed to meet the critical needs of insulin-dependent individuals or those at risk of hypoglycemia in the U.S.
Employees: 11
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
2.13% more ownership
Funds ownership: 1.71% [Q4 2024] → 3.85% (+2.13%) [Q1 2025]
10% less funds holding
Funds holding: 10 [Q4 2024] → 9 (-1) [Q1 2025]
20% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 5
32% less capital invested
Capital invested by funds: $103K [Q4 2024] → $69.8K (-$32.8K) [Q1 2025]
33% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 3
Research analyst outlook
We haven’t received any recent analyst ratings for GCTK.
Financial journalist opinion
Based on 4 articles about GCTK published over the past 30 days
Neutral
GlobeNewsWire
2 days ago
Glucotrack Announces Reverse Stock Split Shareholder Approved Action Meets NASDAQ Panel Hearing Listing Requirements
1-for-60 reverse stock split to become effective as of the opening of trading on June 16, 2025 Rutherford, NJ, June 12, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that it will effect a 1-for-60 reverse stock split (the “Reverse Stock Split”) of its issued and outstanding common stock par value $0.001 per share (the “Common Stock”), effective with the opening of trading on Monday, June 16, 2025. Glucotrack's Common Stock will continue to trade on the Nasdaq Capital Market (“Nasdaq”) under the symbol “GCTK”.
Neutral
GlobeNewsWire
1 week ago
Glucotrack to Showcase Long-Term Continuous Blood Glucose Monitor at American Diabetes Association's 85th Scientific Sessions
Glucotrack to present on next-generation continuous blood glucose monitoring technology in Innovation Hub Poster presentation to highlight insights on safety and performance data from direct blood glucose measurement technology RUTHERFORD, N.J., June 04, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced it will present safety and performance data from its first-in-human trial of its implantable continuous blood glucose monitoring (CBGM) system.
Neutral
GlobeNewsWire
2 weeks ago
Glucotrack Strengthens Board of Directors with Election of Victoria E. Carr-Brendel, PhD
Experienced medical device executive with deep expertise in implantable technologies joins Glucotrack as Company advances development of long-term implantable blood glucose monitoring technology Experienced medical device executive with deep expertise in implantable technologies joins Glucotrack as Company advances development of long-term implantable blood glucose monitoring technology
Neutral
GlobeNewsWire
3 weeks ago
Glucotrack Establishes Patient Advisory Board to Inform Diabetes Technology Development
Patients get a seat at the table in development of long-term implantable continuous blood glucose monitoring technology Patients get a seat at the table in development of long-term implantable continuous blood glucose monitoring technology
Neutral
GlobeNewsWire
1 month ago
Glucotrack Reports First Quarter 2025 Financial Results and Recent Corporate Highlights
On track to implant first patients in long-term, multicenter feasibility study of the fully implantable continuous blood glucose monitor (CBGM) system in Australia in Q3 2025
Neutral
GlobeNewsWire
1 month ago
Glucotrack Announces Ethical Approval for Long-Term Clinical Study of Continuous Blood Glucose Monitor
Long-term clinical evaluation represents key advancement following successful first-in-human study Long-term clinical evaluation represents key advancement following successful first-in-human study
Neutral
GlobeNewsWire
1 month ago
Glucotrack to Participate in FORGETDIABETES, a Prominent European Research Initiative to Develop a Bionic Pancreas
RUTHERFORD, N.J., April 16, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that it will participate in the FORGETDIABETES bionic pancreas initiative that will develop a long-term, automated insulin delivery system that will enable optimal glucose control without patient intervention.
Neutral
GlobeNewsWire
2 months ago
Glucotrack and OneTwo Analytics to Collaborate for Clinical Study Analysis on Its Continuous Blood Glucose Monitor
Next Generation AI-Driven Analytics to Unlock Key Insights from the Ongoing Continuous Blood Glucose Monitoring Clinical Study Data Next Generation AI-Driven Analytics to Unlock Key Insights from the Ongoing Continuous Blood Glucose Monitoring Clinical Study Data
Neutral
GlobeNewsWire
2 months ago
Glucotrack Reports Full Year 2024 Financial Results and Recent Corporate Highlights
Transformational 2024: successfully advanced from preclinical to clinical stage company Strengthened leadership team to drive growth and advance clinical development Investigational Device Exemption (IDE) approval for continuous blood glucose monitoring (CBGM) technology from FDA expected in Q4 2025 Rutherford, NJ, March 31, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today reported financial results and recent corporate highlights for the fourth quarter and full year ended December 31, 2024. “2024 was transformative for Glucotrack as we advanced the development of our CBGM technology and successfully transitioned from a preclinical to a clinical stage company.
Neutral
GlobeNewsWire
2 months ago
Glucotrack to Present First-In-Human Study Results for Continuous Blood Glucose Monitor at the 2025 International Conference on Advanced Technologies & Treatment for Diabetes
Safety and performance data from direct blood glucose measurement technology to be featured at international diabetes technology conference Safety and performance data from direct blood glucose measurement technology to be featured at international diabetes technology conference
Charts implemented using Lightweight Charts™